After certain GLP-1 receptor agonist drugs such as Ozempic and Wegovy were placed on the FDA drug shortage list, specialized pharmacies began compounding semaglutide and other similar peptide-based drugs for patients seeking to use them for weight loss purposes
Combining these medications raises significant concerns about cardiovascular strain, gastrointestinal side effects, and unpredictable drug interactions
The grey market: why buying retatrutide in the UK is dangerous Because demand has outrun supply by several years, an illegal market has filled the gap
Because they handle so much oxygen, mitochondria naturally generate ROS as a byproduct of energy production
Although, as Cooper points out, all weight loss has the potential for muscle loss, so this effect isnt unique to Ozempic
Practical considerations also matter